Unique ID issued by UMIN | UMIN000035705 |
---|---|
Receipt number | R000040671 |
Scientific Title | Multipotentials of new asymmetric cellulose triacetate membrane for on-line hemodiafiltration both in postdilution and predilution |
Date of disclosure of the study information | 2019/01/28 |
Last modified on | 2019/04/26 22:21:22 |
Multipotentials of new asymmetric cellulose triacetate membrane for on-line hemodiafiltration both in postdilution and predilution
Multipotentials of new asymmetric cellulose triacetate membrane for on-line hemodiafiltration both in postdilution and predilution
Multipotentials of new asymmetric cellulose triacetate membrane for on-line hemodiafiltration both in postdilution and predilution
Multipotentials of new asymmetric cellulose triacetate membrane for on-line hemodiafiltration both in postdilution and predilution
Japan |
Dialysis patients treated by OL-HDF.
The patient selection criteria required patients to be 20 years or older, but did not concern gender, inpatient/outpatient classification, medical history, or the presence of complications for the patient. We excluded patients with significant inflammatory symptoms and severe impairment of the liver, heart, lungs, etc.
Nephrology |
Others
NO
This study aimed to elucidate the removal properties of the ATA membrane in OL-HDF compared to those of synthetic polymer membranes as well as examine the influence of the dilution method and substitution volume on the solute removal.
Efficacy
The evaluation items were the removal rate (RR) of B2- microglobulin (B2-MG) and the RR of A1-microglobulin (A1-MG), the removed B2-MG quantity and A1-MG, the albumin leakage quantity, the selective removal index of A1-MG (SRIA), and TMP for each treatment group. The SRIA was calculated as the removed A1-MG quantity divided by the albumin leakage quantity in a single session. We also evaluated the relationship between the removed A1-MG quantity and the albumin leakage quantity
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
5
Treatment
Device,equipment |
TDF20-PV (TDF: Toray Medical Co., Ltd.)
The usage period is 4 weeks.
GDF-21 (GDF: Nikkiso Co., Ltd.)
The usage period is 4 weeks.
MFX-25U eco (MFX: NIPRO)
The usage period is 4 weeks.
FIX-250S eco (FIX-S: NIPRO)
The usage period is 4 weeks.
FIX-250U eco (FIX-U: NIPRO)
The usage period is 4 weeks.
20 | years-old | <= |
Not applicable |
Male and Female
The patient selection criteria required patients to be 20 years or older, but did not concern gender, inpatient/outpatient classification, medical history, or the presence of complications for the patient.
We excluded patients with significant inflammatory symptoms and severe impairment of the liver, heart, lungs, etc.
30
1st name | Yusaku |
Middle name | |
Last name | Tanaka |
Kawashima Hospital
Clinical Engineering Department
770-0011
1-1-39, Kitasako, Tokushima City, Tokushima Prefecture 770-0011, Japan
088-631-0110
yu-tanaka0724@khg.or.jp
1st name | Yusaku |
Middle name | |
Last name | Tanaka |
Kawashima Hospital
Clinical Engineering Department
770-0011
1-1-39, Kitasako, Tokushima City, Tokushima Prefecture 770-0011, Japan
088-631-0110
yu-tanaka0724@khg.or.jp
Kawashima Hospital, Clinical Engineering Department
none
Self funding
Kawashima Hospital
1-1-39, Kitasako, Tokushima City, Tokushima Prefecture, Japan
088-631-0110
yu-tanaka0724@khg.or.jp
NO
2019 | Year | 01 | Month | 28 | Day |
Unpublished
Completed
2019 | Year | 01 | Month | 20 | Day |
2018 | Year | 11 | Month | 01 | Day |
2019 | Year | 01 | Month | 29 | Day |
2019 | Year | 02 | Month | 01 | Day |
2019 | Year | 01 | Month | 28 | Day |
2019 | Year | 04 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040671
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |